Resmetirom Shows Promise in Reducing Atherosclerosis in Preclinical Model
How Does Resmetirom Differ From Existing Cholesterol Drugs?
A new study reveals that the drug resmetirom significantly reduces atherosclerosis in mice fed a high-fat diet, targeting both harmful lipid levels and inflammation in blood vessels. The research, conducted on ApoE−/− mice—a common model for human atherosclerosis—found that resmetirom treatment led to measurable improvements in vascular health after prolonged high-fat diet exposure. These effects were linked to the drug’s action on thyroid hormone receptor beta, which regulates lipid metabolism and inflammatory pathways.
Health news
Vegan Diets May Reduce Gut Bacteria Diversity, Study Finds
Music with beats cuts stress hormone more than pink noise
Epigenetic Shifts Can Trigger Liver Cancer Without DNA Damage
Blood Clots and Brain Tumors Linked by Overactive PlateletsResmetirom, a selective thyroid hormone receptor β agonist, was administered to mice over several weeks while they consumed a diet high in fats and cholesterol. Researchers observed a notable decrease in atherosclerotic plaque formation in the aorta, accompanied by lower levels of circulating triglycerides and LDL cholesterol. Importantly, the treatment also reduced markers of vascular inflammation, such as macrophage infiltration and cytokine expression, suggesting a dual benefit beyond lipid lowering alone. The study highlights how modulating thyroid hormone signaling can simultaneously address two key drivers of atherosclerosis: dyslipidemia and chronic inflammation.
What Are the Implications for Human Treatment?
Unlike statins, which primarily lower LDL cholesterol by inhibiting hepatic synthesis, resmetirom works by activating thyroid hormone receptor β in the liver, thereby increasing fatty acid oxidation and reducing lipogenesis. This mechanism not only improves lipid profiles but also appears to dampen inflammatory responses in the arterial wall. In the mouse model, resmetirom achieved these effects without inducing tachycardia or other typical signs of thyroid hormone excess, indicating a favorable tissue-specific action. Researchers noted that the drug’s selectivity for the β isoform over the α isoform likely contributed to its cardiovascular safety profile in this preclinical setting.
The findings support further investigation of resmetirom as a potential therapy for patients with atherosclerosis who struggle to manage both lipid levels and inflammation with current treatments. While the drug is already approved for certain metabolic liver conditions, its repurposing for cardiovascular risk reduction would require clinical trials demonstrating similar benefits in humans. Experts caution that mouse results do not always translate directly to people, but the mechanistic plausibility and observed safety signals are encouraging. If confirmed in human studies, resmetirom could offer a novel dual-action approach to slowing or even reversing atherosclerotic disease.
What is atherosclerosis and why is it dangerous? Atherosclerosis is the buildup of fats, cholesterol, and other substances in artery walls, forming plaques that can narrow vessels and increase the risk of heart attack or stroke. It results from a combination of high lipid levels and chronic inflammation, making dual-targeting therapies particularly valuable.
Frequently Asked Questions
How was the effectiveness of resmetirom measured in the study? Researchers assessed plaque size in the aorta, blood lipid levels, and inflammatory markers such as immune cell presence and inflammatory proteins in vascular tissue. Improvements across these indicators indicated reduced disease progression.
Is resmetirom currently used to treat heart disease? No, resmetirom is not yet approved for atherosclerosis or cardiovascular disease. It is currently indicated for certain liver conditions involving fat metabolism, but its potential vascular benefits are under active scientific evaluation.